RARE Ultragenyx Pharmaceutical Inc.

-6  -8%
Previous Close 78.36
Open 73.11
Price To book 6.82
Market Cap 3.00B
Shares 41,726,000
Volume 2,164,045
Short Ratio 11.26
Av. Daily Volume 456,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. BLA filing due 1H 2017.
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data due 2H 2017.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 enrolment completed July 2016. Data due 1H 2017.
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
Tumor-induced osteomalacia (TIO)
Phase 3 enrollment commenced October 2016.
X-Linked Hypophosphatemia (XLH) - pediatric
Phase 2 initiated March 2014. Data released March 22, 2017 - primary endpoint not met.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned for 2017.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017
  2. Is It Time To Buy Ultragenxy?
  3. Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
  4. Biotech Premarket Movers: Insys, Ultragenyx, Alexion
  5. Ultragenyxs’ Seizure Drug Fails Study
  6. Ultragenyx falls on results of seizure medication study
  7. Ultragenyx seizure drug fails mid-stage study
  8. Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
  9. 4:05 pm Ultragenyx Pharma announces topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures; study did not meet the primary endpoint
  10. Ultragenyx to Present at Upcoming Investor Conferences
  12. Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical
  13. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report
  14. Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT
  15. Ultragenyx reports 4Q loss
  16. Ultragenyx reports 4Q loss
  17. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  18. Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
  19. Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
  20. Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More